Cases of gallbladder side effects related to Byetta, Trulicity, Ozempic, and Adlyxin were reported in this August 2022 medical journal JAMA Internal Medicine article, “Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration”, which starts with the following:
The required labeling for some glucagon-like peptide-1 receptor agonists (GLP-1 RAs) indicated for glycemic control in patients with type 2 diabetes include warnings and precautions regarding acute gallbladder disease in the US Prescribing Information (the prescribing information approved by the US Food and Drug Administration [FDA]), while others do not. The FDA recently reviewed the FDA Adverse Event Reporting System (FAERS) to identify cases of acute cholecystitis (AC) associated with the GLP-1 RA products that did not have warnings and precautions regarding acute gallbladder disease.
We get more details from this August 30, 2022 MedPage Today news report, “FDA Data Link Diabetes Drug Class to Gallbladder Disease”:
An analysis of FDA’s reporting system for adverse events turned up three dozen cases of [ gallbladder side effects ] in patients taking glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes or weight loss, including three deaths.
From 2005 to 2016, postmarketing cases of acute cholecystitis were identified in 21 patients taking exenatide (Byetta), in seven taking dulaglutide (Trulicity), in seven on semaglutide (Ozempic), and in one patient taking lixisenatide (Adlyxin)….
We will continue to watch for cases of gallbladder side effects related to Byetta, Trulicity, Ozempic, and Adlyxin for diabetes or weight loss.[View article at original source]
Strictly Confidential, No Obligation